Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma.
Anderson, CP; Matthay, KK; Perentesis, JP; Neglia, JP; Bailey, HH; Villablanca, JG; Groshen, S; Hasenauer, B; Maris, JM; Seeger, RC; et al.
Pediatric Blood and Cancer.
2015;
62:1739-1746.
Overcoming adaptive therapy resistance in AML by targeting immune response pathways.
Melgar, K; Walker, MM; Jones, LM; Bolanos, LC; Hueneman, K; Wunderlich, M; Jiang, J; Wilson, KM; Zhang, X; Sutter, P; et al.
Science Translational Medicine.
2019;
11:eaaw8828-eaaw8828.
Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016).
Widemann, BC; Lu, Y; Reinke, D; Okuno, SH; Meyer, CF; Cote, GM; Chugh, R; Milhem, MM; Hirbe, AC; Kim, A; et al.
Sarcoma.
2019;
2019:1-8.
miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential.
Meyer, SE; Muench, DE; Rogers, AM; Newkold, TJ; Orr, E; O'Brien, E; Perentesis, JP; Doench, JG; Lal, A; Morris, PJ; et al.
The Journal of Experimental Medicine.
2018;
215:2115-2136.
KLF5 controls glutathione metabolism to suppress p190-BCRABL+ B-cell lymphoblastic leukemia.
Zhang, C; D'Alessandro, A; Wellendorf, AM; Mohmoud, F; Serrano-Lopez, J; Perentesis, JP; Komurov, K; Alexe, G; Stegmaier, K; Whitsett, JA; et al.
Oncotarget.
2018;
9:29665-29679.
Proton therapy for pediatric malignancies: Fact, figures and costs. A joint consensus statement from the pediatric subcommittee of PTCOG, PROS and EPTN.
Weber, DC; Habrand, JL; Hoppe, BS; Kayser, CH; Laack, NN; Langendijk, JA; MacDonald, SM; McGovern, SL; Pater, L; Perentesis, JP; et al.
Radiotherapy and Oncology.
2018;
128:44-55.
An Update From the Pediatric Proton Consortium Registry.
Hess, CB; Indelicato, DJ; Paulino, AC; Hartsell, WF; Hill-Kayser, CE; Perkins, SM; Mahajan, A; Laack, NN; Ermoian, RP; Chang, AL; et al.
Frontiers in Oncology.
2018;
8.
Viral surveillance using PCR during treatment of AML and ALL.
Dixon, SB; Lane, A; O'Brien, MM; Burns, KC; Mangino, JL; Breese, EH; Absalon, MJ; Perentesis, JP; Phillips, CL.
Pediatric Blood and Cancer.
2018;
65:e26752-e26752.
A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).
Geller, JI; Perentesis, JP; Liu, X; Minard, CG; Kudgus, RA; Reid, JM; Fox, E; Blaney, SM; Weigel, BJ.
Pediatric Blood and Cancer.
2017;
64:e26565-e26565.
Long-term morbidity after staging laparotomy for Hodgkin lymphoma.
Lobeck, I; Rymeski, B; Burns, K; Nagarajan, R; Correll, J; Kent, D; Dasgupta, R.
Journal of Pediatric Surgery.
2017;
52:1430-1432.